Eligibility Criteria: (1) Prospective studies of CSF biomarkers’ performance for predicting conversion from MCI to AD/dementia; (2) inclusion of Aβ42 and T-tau and/or p-tau. This evidence concerns the gene MAPT and Alzheimer disease.